Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose

Oritavancin is a novel glycopeptide currently being developed for the treatment of complicated skin and skin structure infections (cSSSI), including those caused by multidrug resistant gram-positive pathogens. The disposition of oritavancin in skin structures was investigated using a cantharide-indu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Antimicrob Agents Chemother
Päätekijät: Fetterly, Gerald J., Ong, Christine M., Bhavnani, Sujata M., Loutit, Jeffrey S., Porter, Steven B., Morello, Lisa G., Ambrose, Paul G., Nicolau, David P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology (ASM) 2005
Aiheet:
Pharmacology
Linkit:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC538852/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15616289/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.49.1.148-152.2005
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia